Render Target: STATIC
Render Timestamp: 2024-12-13T11:03:50.523Z
Commit: 611277b6de3cd1bb065350b6ef8d63df412b7185
XML generation date: 2024-09-20 06:21:14.078
Product last modified at: 2024-05-30T07:03:17.876Z
Cell Signaling Technology Logo
View Featured Offers >>
1% for the planet logo
PDP - Template Name: IHC Kit
PDP - Template ID: *******35f95d7
  1. Products /
  2. Primary Antibodies /
  3. PD-L1, FoxP3, CD8α Multiplex IHC Antibody Panel

PD-L1, FoxP3, CD8α Multiplex IHC Antibody Panel #78701

Inquiry Info. # 78701

Please see our recommended alternatives.

    Product Information

    Product Description

    The PD-L1, FoxP3, CD8α Multiplex IHC Antibody Panel enables researchers to simultaneously detect these targets in paraffin-embedded tissues using tyramide signal amplification. Each antibody in the panel has been validated for this approach. For recommended staining conditions optimized specifically for this antibody panel please refer to Table 1 on the Data Sheet.

    Specificity / Sensitivity

    Each antibody in this panel recognizes endogenous levels of its specific target protein.

    Source / Purification

    Monoclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human PD-L1 protein, recombinant protein specific to human FoxP3, or a synthetic peptide corresponding to residues near the carboxy terminus of human CD8α protein.

    Background

    The field of cancer immunotherapy is focused on empowering the immune system to fight cancer. This approach has seen recent success in the clinic with targeting immune checkpoint control proteins, such as PD-1 (1,2). Despite this success, clinical biomarkers that predict response to therapeutic strategies involving PD-1 receptor blockade are still under investigation (3-5). While PD-L1 expression has been linked with an increased likelihood of response to anti-PD-1 therapy, research studies have shown that additional factors, such as tumor-immune infiltration and the ratio of effector to regulatory T cells within the tumor, could play a significant role in predicting treatment outcome (6-9).
    Programmed cell death 1 ligand 1 (PD-L1) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. The PD-L1 ligand binds the PD-1 transmembrane receptor and inhibits T cell activation. PD-L1 is expressed in several tumor types, including melanoma, ovary, colon, lung, breast, and renal cell carcinomas (10-12).
    FoxP3 is a transcription factor that is crucial for the development of T cells with regulatory properties (Treg) (13). Mutations in FoxP3 are associated with immune dysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome (IPEX) (15), while overexpression in mice causes severe immunodeficiency (15). Research studies have shown that FoxP3 functions as a tumor suppressor in several types of cancer (16-18).
    CD8 (Cluster of Differentiation 8) is a disulphide-linked heterodimer consisting of α and β subunits. On T cells, CD8 is the coreceptor for the TCR, and these two distinct structures recognize the Antigen–Major Histocompatibility Complex (MHC). CD8 ensures specificity of the TCR–antigen interaction, prolongs the contact between the T cell and the antigen presenting cell, and the α chain recruits the tyrosine kinase Lck, which is essential for T cell activation (19).
    1. Topalian, S.L. et al. (2012) N Engl J Med 366, 2443-54.
    2. Piccinini, M. et al. (2014) Comput Methods Biomech Biomed Engin 17, 1403-17.
    3. Chakravarti, N. and Prieto, V.G. (2015) Transl Lung Cancer Res 4, 743-51.
    4. Sholl, L.M. et al. (2016) Arch Pathol Lab Med , .
    5. Carbognin, L. et al. (2015) PLoS One 10, e0130142.
    6. Tokito, T. et al. (2016) Eur J Cancer 55, 7-14.
    7. Tumeh, P.C. et al. (2014) Nature 515, 568-71.
    8. Feng, Z. et al. (2015) J Immunother Cancer 3, 47.
    9. Baine, M.K. et al. (2015) Oncotarget 6, 24990-5002.
    10. Dong, H. et al. (2002) Nat Med 8, 793-800.
    11. Thompson, R.H. et al. (2006) Cancer Res 66, 3381-5.
    12. Pardoll, D.M. (2012) Nat Rev Cancer 12, 252-64.
    13. Ochs, H.D. et al. (2007) Immunol Res 38, 112-21.
    14. Bennett, C.L. et al. (2001) Nat Genet 27, 20-1.
    15. Kasprowicz, D.J. et al. (2003) J Immunol 171, 1216-23.
    16. Zuo, T. et al. (2007) Cell 129, 1275-86.
    17. Zuo, T. et al. (2007) J Clin Invest 117, 3765-73.
    18. Wang, L. et al. (2009) Cancer Cell 16, 336-46.
    19. Zamoyska, R. (1994) Immunity 1, 243-6.

    Database Links

    UniProt ID: Q9NZQ7 , P01732 , Q9BZS1


    Entrez-Gene Id: 29126 , 925 , 50943


    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    Cy and CyDye are registered trademarks of GE Healthcare.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.